{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:06:46Z","timestamp":1784264806526,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112825","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:44:12Z","timestamp":1784263452000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetic Characteristics of Chronic Lymphocytic Leukemia Patients: A Single-Center Study From Morocco"],"prefix":"10.7759","author":[{"given":"Monsif","family":"Fadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"El Ouafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaimaa","family":"Hilali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Azzahra","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouama","family":"Bouanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152732","article-title":"Chronic lymphocytic leukemia: prognostic factors in the era of novel drugs","volume":"16","author":"Urso A","year":"2024","unstructured":"Urso A, Martino EA, Cuneo A, Gentile M, Rigolin GM. Chronic lymphocytic leukemia: prognostic factors in the era of novel drugs. Cancers (Basel). 2024, 16:10.3390\/cancers16152732","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2023.103410","article-title":"Cytogenetics in the management of chronic lymphocytic leukemia: guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH)","volume":"71","author":"Nguyen-Khac F","year":"2023","unstructured":"Nguyen-Khac F, Balogh Z, Chauzeix J, Veronese L, Chapiro E. Cytogenetics in the management of chronic lymphocytic leukemia: guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH). Curr Res Transl Med. 2023, 71:103410. 10.1016\/j.retram.2023.103410","journal-title":"Curr Res Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186684","article-title":"Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review","volume":"103","author":"Autore F","year":"2018","unstructured":"Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica. 2018, 103:931-8. 10.3324\/haematol.2017.186684","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas P","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, et al.. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019, 133:1205-16. 10.1182\/blood-2018-09-873083","journal-title":"Blood"},{"key":"ref5","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes E","year":"1994","unstructured":"Matutes E, Owusu-Ankomah K. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994, 8:1640-1645.","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin TJ","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999, 94:1848-54. 10.1182\/blood.V94.6.1848","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek M","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019, 94:1266-87. 10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps TJ","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, et al.. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017, 3:16096. 10.1038\/nrdp.2016.96","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz T","year":"2010","unstructured":"Zenz T, Mertens D, K\u00fcppers R, D\u00f6hner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010, 10:37-50. 10.1038\/nrc2764","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner H","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, et al.. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000, 343:1910-6. 10.1056\/NEJM200012283432602","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek M","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al.. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018, 131:2745-60. 10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/435983","article-title":"Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go","volume":"2014","author":"Puiggros A","year":"2014","unstructured":"Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int. 2014, 2014:435983. 10.1155\/2014\/435983","journal-title":"Biomed Res Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh SA","year":"2016","unstructured":"Parikh SA, Shanafelt TD. Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol. 2016, 43:233-40. 10.1053\/j.seminoncol.2016.02.009","journal-title":"Semin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2410003","article-title":"BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance","volume":"17","author":"Robak T","year":"2024","unstructured":"Robak T, Witkowska M, Wolska-Washer A, Robak P. BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance. Expert Rev Hematol. 2024, 17:781-96. 10.1080\/17474086.2024.2410003","journal-title":"Expert Rev Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst B","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, et al.. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024, 35:762-8. 10.1016\/j.annonc.2024.06.016","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01482-6","article-title":"Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease","volume":"26","author":"Stumpf J","year":"2024","unstructured":"Stumpf J, Al-Sawaf O. Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease. Curr Oncol Rep. 2024, 26:136-46. 10.1007\/s11912-023-01482-6","journal-title":"Curr Oncol Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511915-cytogenetic-characteristics-of-chronic-lymphocytic-leukemia-patients-a-single-center-study-from-morocco","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:44:19Z","timestamp":1784263459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511915-cytogenetic-characteristics-of-chronic-lymphocytic-leukemia-patients-a-single-center-study-from-morocco"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.112825","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}